Press releaseGlobe Newswire
Inhibikase Therapeutics
IKT · NASDAQ
$1.71+$0.065 (+3.95%)TodayMarket closed ·
Prev close $1.65
Latest news
- Press releaseGlobe Newswire
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
- News
Inhibikase Therapeutics Says FDA Grants Orphan Drug Designation To Its Lead Product Candidate IKT-001, Prodrug Of Imatinib Mesylate, For Treatment Of PAH
- Press releaseGlobe Newswire
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
- Press releaseGlobe Newswire
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
- Press releaseGlobe Newswire
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
- Press releaseGlobe Newswire
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsAvi Kapoor
Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releasePRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Dow Surges 350 Points; US Crude Oil Stocks Increase
- NewsAvi Kapoor
Crude Oil Edges Lower; US Wholesale Inventories Rise 0.1% In August
- NewsAvi Kapoor
Dow Jumps Over 100 Points; Helen Of Troy Posts Upbeat Q2 Results
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.